Sugi Predict

Sugi Predict / Targets / PARP8

PARP8

Protein mono-ADP-ribosyltransferase PARP8 · Q8N3A8 · PARP8 on Sugi Atlas →

3,989 patent compounds predicted against PARP8, 3,432 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Olaparib Olaparib (SCHEMBL426568) 1.00 1/20
Talazoparib Talazoparib (SCHEMBL2046086) 1.00 1/20
Talazoparib Talazoparib (SCHEMBL2295997) 1.00 1/20
Talazoparib Talazoparib (SCHEMBL2299348) 1.00 1/20
Pamiparib Pamiparib (SCHEMBL15084918) 1.00 1/20
SCHEMBL15287300 SCHEMBL15287300 1.00 1/20
SCHEMBL2043333 SCHEMBL2043333 0.88 1/20
SCHEMBL2312803 SCHEMBL2312803 0.88 1/20
SCHEMBL2313537 SCHEMBL2313537 0.88 1/20
SCHEMBL9280839 SCHEMBL9280839 0.83 1/20
SCHEMBL14718792 SCHEMBL14718792 0.83 1/20
SCHEMBL2043160 SCHEMBL2043160 0.81 1/20
SCHEMBL2311187 SCHEMBL2311187 0.81 1/20
SCHEMBL2314408 SCHEMBL2314408 0.81 1/20
SCHEMBL2379944 SCHEMBL2379944 0.81 1/20
SCHEMBL2382839 SCHEMBL2382839 0.81 1/20
Talazoparib Talazoparib (SCHEMBL2717160) 0.80 1/20
Talazoparib Talazoparib (SCHEMBL14723419) 0.80 1/20
SCHEMBL1689371 SCHEMBL1689371 0.80 1/20
SCHEMBL78306 SCHEMBL78306 0.80 1/20

Clinical trials — most relevant to PARP8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) PHASE1/PHASE2COMPLETED
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib PHASE2COMPLETED
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure PHASE2UNKNOWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation PHASE2COMPLETED
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma PHASE2COMPLETED
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Olaparib In Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) PHASE2RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems PHASE1WITHDRAWN
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
FTT PET/CT in Pancreatic Neuroendocrine Tumors PHASE1RECRUITING
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer PHASE1UNKNOWN
ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer PHASE1COMPLETED
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer PHASE1COMPLETED
Pre-Operative Radiation and Veliparib for Breast Cancer PHASE1COMPLETED
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors PHASE1COMPLETED
PET Imaging of PARP Activity in Cancer EARLY_PHASE1UNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer nanNO_LONGER_AVAILABLE
Sirtuin1 in COVID19 Patients nanUNKNOWN
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PARP8 binder may also engage these)

ProteinNameSimilarity
Q3UD82 — 1.000 Q3UD82 →
Q3B7T1 — 0.984 Q3B7T1 →
Q6DEZ2 — 0.983 Q6DEZ2 →
Q8K2L8 — 0.983 Q8K2L8 →
P49140 — 0.983 P49140 →
Q6GQV7 — 0.982 Q6GQV7 →
P79457 — 0.982 P79457 →
A0JMR6 — 0.981 A0JMR6 →
Q8CF97 — 0.981 Q8CF97 →
Q6GVH5 — 0.981 Q6GVH5 →
O54828 — 0.981 O54828 →
Q96JH7 — 0.980 Q96JH7 →
Q921C3 — 0.980 Q921C3 →
O70546 — 0.980 O70546 →
Q93ZS1 — 0.980 Q93ZS1 →
Q9EQM6 — 0.980 Q9EQM6 →
Q8WYQ5 — 0.980 Q8WYQ5 →
Q28C33 — 0.980 Q28C33 →
O17482 — 0.980 O17482 →
Q02225 — 0.979 Q02225 →
Q62925 — 0.979 Q62925 →
P70662 — 0.979 P70662 →
Q5R9R1 — 0.979 Q5R9R1 →
O44431 — 0.978 O44431 →
Q8NAN2 — 0.978 Q8NAN2 →
F4HRV8 — 0.978 F4HRV8 →
Q8VDY4 — 0.978 Q8VDY4 →
Q7YQJ9 — 0.978 Q7YQJ9 →
Q5SV77 — 0.978 Q5SV77 →
Q8AVJ1 — 0.978 Q8AVJ1 →